[PDF] Top 20 Psychosocial Function During Treatment for Familial Hypercholesterolemia

... It has been suggested that the identification of children who are at risk for cardiovascular disease is unnecessary and may be harmful.9”#{176} Thus, some au- thors disagree with the exp[r] ... See full document

... Familial hypercholesterolemia is a serious genetic dis- order affecting patients in the early years of ...Various treatment options are available at the ... See full document

... Familial hypercholesterolemia (FH) is an inherited common autosomal Mendelian disorder of lipoprotein metabolism with a population prevalence of 1 in ...and treatment of FH patients will reduce ... See full document

... Heterozygous familial hypercholesterolemia (FH) is a genetic disorder character- ized by high low-density lipoprotein cholesterol levels from birth, which exposes the arteries to high levels of atherogenic ... See full document

... the treatment of adult patients with heterozygous familial hypercholesterolemia (heFH), as the result of numerous studies in patients with primary hypercholesterolemia or ... See full document

... Abstract: Familial hypercholesterolemia (FH) is an autosomal dominant condition with a population prevalence of one in 300–500 (heterozygous) that is characterized by high levels of low-density lipoprotein ... See full document

... bow a concentration of chobesterob in the serum as does a low- or cholesterol-free diet with added sitosterol. There was no weight loss in either child during the course[r] ... See full document

... Seven prepubertal children (age range 5.3 to 10.8 years) with severe heterozygous familial hyper- cholesterolemla (serum cholesterol concentration 416 ± 85 mg/dL and low-density lipoprot[r] ... See full document

... in treatment of homozygous patients – it is practically a case of life- saving ...Homozygous familial hypercholesterolaemia occurs in a frequency 1 : ... See full document

... In the post-hoc analysis of the FOURIER trial, which included 27,564 participants, the effects of adding evolocu- mab (either 140 mg subcutaneously every 2 weeks or 420 mg subcutaneously monthly) versus matching placebo ... See full document

... Lovastatin therapy in receptor-negative homozygous familial hypercholesterolemia: lack of effect on low-density lipoprotein concentrations or turnover. Ducobu J, Brasseur D, Chaudron JM,[r] ... See full document

... especially in children (Sjouke et al., 2016). Although not considered to be appropriate for prenatal screening, because it is so eminently treatable, some families might appreciate knowing the discrete genetic basis for ... See full document

... of treatment, transaminases returned to normal in all ...transaminase during mipomersen treatment is unclear, and it was not seen in preclinical ... See full document

... whether hypercholesterolemia is associated with MPO up-regulation and whether MPO serum levels are affected by cholesterol ...with Familial Hypercholes- terolemia (FH) undergoing LDL (Low Density ... See full document

... (mean age 13 ± 12) than those with arcus (mean age 31 ± 11). The data on these 17 patients was collected over sev- eral decades and in some cases is ongoing. With the advent of newer therapies such as LDL removal by ... See full document

... showing primary hyper-LDL cholesterolemia (>160 mg/dl). Exclusion criteria of the present study were FH patients with a homozygous gene mutation, patients under LDL apheresis therapy or any immunomodulatory ... See full document

... 2-year treatment with pravastatin in 8–18-year-old children with FH induced a significant regression of carotid intima-media thickness without any adverse events; this finding suggests “the younger, the better” ... See full document

... Abstract: Familial hypercholesterolemia (FH) is a common inherited disorder that results in premature ...of treatment can modify disease progression and ...mutations. Familial defective Apo B ... See full document

... 22-Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection. Evaluation and treatment of high blood cholesterol in adults (Adult treatment Panel III). JAMA 2001 May 16; ... See full document

... sis begins early in life for individuals with FH (especially in HoFH), childhood screening is intended to facilitate early identification and treatment. Despite the theo- retical benefits of the National Heart ... See full document